AstraZeneca Financials - Benzinga

AstraZeneca PLC

AZNNYSE

Trade with Public

Trade with Public

$164.77

3.141.94%

가까이에: Sep 2, 5:00 PM EST

$164.17

2.541.57%

프리마켓: 8:09 AM EST

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 배당금 비교 옵션 주식 보고서

AstraZeneca Financials

AstraZeneca (AZN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks

Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighed on expectations and investors reacted.

Vandana Singh

Dow Gains Over 250 Points Amid Lower Oil Prices: Investor Sentiment Weakens, Greed Index Remains In ‘Fear’ Zone

U.S. stocks mixed as Dow gains 250 points amid decline in oil prices. CNN Money Fear and Greed Index shows market sentiment in Fear zone.

Avi Kapoor

Pipeline Speed Bump Doesn't Shake AstraZeneca's $80 Billion Revenue Ambition

AstraZeneca (AZN) Q2 2026: EPS beats estimates at $2.63 despite missing revenue targets. Oncology sales up 16%. Get the full recap.

Vandana Singh

PRO
AstraZeneca Reconfirms FY2026 Guidance, Expecting Mid-To-High Single-Digit Revenue Growth And Low Double-Digit Core EPS Growth At Constant Exchange Rates

Benzinga Newsdesk

PRO
AstraZeneca Q2 Adj. EPS $2.63 Beats $2.48 Estimate, Sales $15.384B Miss $15.459B Estimate

AstraZeneca (NASDAQ:AZN) reported quarterly earnings of $2.63 per share which beat the analyst consensus estimate of $2.48 by 6.05 percent. This is a 141.28 percent increase over earnings of $1.08 per share from the

Benzinga Newsdesk

Tempus AI's Big Pharma AI Partnerships Are Getting Bigger And Stickier

Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook amid strong AI & diagnostic demand.

Lekha Gupta

© 2026 Benzinga | All Rights Reserved